GENE ONLINE|News &
Opinion
Blog

2021-04-26| R&D

Recent Advances in Triple Negative Breast Cancer Treatments

by Ruchi Jhonsa
Share To
Triple-negative breast cancer (TNBC) defined by lack of estrogen, progesterone, and the HER2 receptor accounts for 15% of all newly diagnosed breast cancers. With limited treatment options, the median overall survival of these patients is just over one year. TNBC as compared to other subtypes of breast cancers are more likely to have a robust immune infiltrate and have a high level of tumor-infiltrating lymphocytes.
They can also have a higher level of PD-L1 expression and are generally genetically unstable and have a high tumor mutation burden. This makes this tumor type amenable to different therapies.

GO Prime with only $1.49 now

LATEST
Finnish Study Finds Brain Biomarkers for Alzheimer’s Detectable in Middle Age
2025-07-14
Blood Test Developed at Medical University of Vienna Predicts Multiple Sclerosis Risk Years Before Symptoms
2025-07-14
University of Tokyo Researchers Develop In Vivo System to Study Senescent Cells in Aging
2025-07-14
Relmada Therapeutics Ends Development of Depression Drug Esmethadone and Terminates Licensing Agreement
2025-07-14
Takeda Reports Positive Phase 3 Trial Results for Oveporexton in Narcolepsy Treatment
2025-07-14
Takeda Pharmaceuticals Reports Positive Phase 3 Trial Results for Narcolepsy Drug Targeting Daytime Sleepiness and Cataplexy
2025-07-14
Takeda Reports Positive Phase 3 Trial Results for Oveporexton Targeting Orexin Proteins in Narcolepsy Treatment
2025-07-14
EVENT
2025-07-23
BIO Asia–Taiwan 2025
Taipei, Taiwan
2025-08-08
HEALTHY AGEING TECH SHOW
Taipei, Taiwan
2025-08-09
MEDINFO 2025
Taipei, Taiwan
2025-09-03
BIO ASIA PACIFIC 2025
Bangkok, Thailand
2025-09-10
BIOHK 2025
Hong Kong
2025-10-01
Medical Japan 2025
Osaka, Japan
Scroll to Top